Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis

Sherman, 2004, Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis, Cancer, 100, 1045, 10.1002/cncr.20080 Stany, 2010, Clinical decision making using ovarian cancer risk assessment, AJR Am J Roentgenol, 194, 337, 10.2214/AJR.09.3669 Kataoka, 2010, Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo, FEBS J, 277, 2230, 10.1111/j.1742-4658.2010.07640.x Nagakawa, 2005, Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer, Eur Urol, 48, 686, 10.1016/j.eururo.2005.05.020 Comoglio, 1993, Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells, EXS, 65, 131 Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product, Science, 251, 802, 10.1126/science.1846706 Di Renzo, 1994, Overexpression of the Met/HGF receptor in ovarian cancer, Int J Cancer, 58, 658, 10.1002/ijc.2910580507 Rosen, 1994, Scatter factor and the c-Met receptor: a paradigm for mesenchymal/epithelial interaction, J Cell Biol, 127, 1783, 10.1083/jcb.127.6.1783 Tanaka, 2004, Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma, Scand J Gastroenterol, 39, 754, 10.1080/00365520410005973 Maulik, 2002, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition, Cytokine Growth Factor Rev, 13, 41, 10.1016/S1359-6101(01)00029-6 Tanimoto, 2008, Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor, J Med Investig, 55, 106, 10.2152/jmi.55.106 Taniguchi, 1997, Increase in the circulating level of hepatocyte growth factor in gastric cancer patients, Br J Cancer, 75, 673, 10.1038/bjc.1997.120 Baykal, 2003, Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas, Gynecol Oncol, 88, 123, 10.1016/S0090-8258(02)00073-2 Seidel, 1998, Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group, Blood, 91, 806, 10.1182/blood.V91.3.806 Corps, 1997, Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-Met, Int J Cancer, 73, 151, 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I Sawada, 2007, c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion, Cancer Res, 67, 1670, 10.1158/0008-5472.CAN-06-1147 Bu, 2011, HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma, Lab Invest, 91, 124, 10.1038/labinvest.2010.136 Sowter, 1999, Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells, Int J Cancer, 83, 476, 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V Baykal, 2003, Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts, Int J Gynecol Cancer, 13, 771, 10.1111/j.1525-1438.2003.13326.x Kommoss, 2009, Virchows Arch, 454, 249, 10.1007/s00428-009-0725-y Tavassoli, F.A., Devilee, P., ed. Pathology and genetics of tumours of the breast and female genital organs World Health Organization classification of tumours, ed. P. Kleihues, Sobin, L.H. Vol. 1. 2003, International Agency for Research on Cancer: Lyon. 432. Reifenberger, 1996, Epidermal growth factor receptor expression in oligodendroglial tumors, Am J Pathol, 149, 29 Ren, 2005, Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas, Clin Cancer Res, 11, 6190, 10.1158/1078-0432.CCR-04-2553 But, 1996, Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer, Gynecol Oncol, 63, 166, 10.1006/gyno.1996.0301 Cooper, 2002, Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer, Obstet Gynecol, 100, 59, 10.1016/S0029-7844(02)02057-4 Vasilev, 1988, Serum CA 125 levels in preoperative evaluation of pelvic masses, Obstet Gynecol, 71, 751 Bast, 2005, New tumor markers: CA125 and beyond, Int J Gynecol Cancer, 15, 274, 10.1111/j.1525-1438.2005.00441.x Wader, 2008, Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma, Eur J Haematol, 81, 380 Toiyama, 2009, Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients, Int J Cancer, 125, 1657, 10.1002/ijc.24554 Mizuguchi, 2009, Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy, J Gastrointest Surg, 13, 325, 10.1007/s11605-008-0711-8 Parrott, 2000, Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer, Biol Reprod, 62, 491, 10.1095/biolreprod62.3.491 Christensen, 2005, c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, Cancer Lett, 225, 1, 10.1016/j.canlet.2004.09.044 Wang, 2010, Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy, Acta Pharmacol Sin, 31, 1181, 10.1038/aps.2010.106 Liu, 2010, Developing c-MET pathway inhibitors for cancer therapy: progress and challenges, Trends Mol Med, 16, 37, 10.1016/j.molmed.2009.11.005 Saga, 2001, Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival, Gene Ther, 8, 1450, 10.1038/sj.gt.3301553 Zillhardt, 2010, An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis, Neoplasia, 12, 1, 10.1593/neo.09948